

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1-13 (Previously Canceled)

Claim 14 (Currently Amended): A method for prevention or treatment of atherosclerosis in a subject, comprising administering a therapeutically effective amount of an immunological oral tolerance-inducing composition comprising one or more active components selected from the group consisting of ~~modified low density lipoprotein~~, oxidized low density lipoprotein (Ox LDL), ~~heat shock protein 60/65 (HSP 60/65), beta₂-glycoprotein 1 (β₂GP-1) and malondialdehyde LDL (MDA-LDL) functional derivatives thereof~~ and a pharmaceutically acceptable carrier for oral administration, wherein said administration is in a sufficient amount to induce production of IL-10 or TGFβ, ~~and to suppress IFN-γ, and to suppress a type 1 T cell cytokine pattern~~ thereby inhibiting at least one atherosclerosis-related symptom in said subject.

Claim 15-17 (Previously Cancelled)

Claim 18 (Cancelled)

Claim 19 (Previously Amended) The method according to claim 14, wherein said active component is oxidized low density lipoprotein (Ox LDL).

Claim 20 (Cancelled)

Claim 21-25 (Previously Cancelled)

Claim 26 (Currently Amended): The method according to claim 14, wherein said active component functional derivative is malondialdehyde LDL (MDA-LDL).

Claim 27 (New): A method for prevention or treatment of atherosclerosis in a subject, comprising administering a therapeutically effective amount of an immunological oral tolerance-

inducing composition consisting of modified low density lipoprotein and a pharmaceutically acceptable carrier for oral administration, wherein said administration is in a sufficient amount to induce production of IL-10 or TGF β and to suppress IFN- γ , thereby inhibiting at least one atherosclerosis-related symptom in said subject.

Claim 28 (New) A method for prevention or treatment of atherosclerosis in a subject, comprising administering a therapeutically effective amount of an immunological oral tolerance-inducing composition comprising one or more active components selected from the group consisting of human modified low density lipoprotein and human oxidized low density lipoprotein and a pharmaceutically acceptable carrier for oral administration, wherein said administration is in a sufficient amount to induce production of IL-10 or TGF β and to suppress IFN- γ , thereby inhibiting at least one atherosclerosis-related symptom in said subject.